Dinutuximab Beta at the HUS and the Toulouse Oncopole

Neuroblastoma Clinical Trial

— DNB  

Official title:

Dinutuximab Beta at the Strasbourg University Hospitals (HUS) and the Toulouse Oncopole: Comparative Analysis of Patient Pathways, Associated Costs and Quality of Life According to Traditional Hospitalization or Hospital at Home (HAD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06275334
• Other study ID #: 9133
• Status: Recruiting
• Start date: November 28, 2023
• Est. completion date: November 28, 2024

Study information

• Verified date: February 2024
• Source: University Hospital, Strasbourg, France
• Contact: Anne EL AATMANI, Pharm, PhD
• Phone: 33 3 88 12 78 06
• Email: Anne.ELAATMANI[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study the investigators wish to describe the cohort of pediatric patients suffering from neuroblastoma and treated with Dinutuximab and to compare the costs and quality of life between the two French centers, the University Hospital of Strasbourg (HUS) and the Oncopole of Toulouse.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: November 28, 2024
• Est. primary completion date: November 2024
• Gender: All
• Age group: 2 Years to 25 Years

Eligibility

Inclusion Criteria:

• Subjects aged 2 years to 25 years

• Male or female gender

• Subjects suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023.

• Subject (and/or holders of parental authority) not opposing, after information, the reuse of the child's data for the purposes of this research and agreeing to respond to the quality of life survey.

Exclusion Criteria:

• Patient or parents of the minor having expressed their opposition to participating in the study.

• specific clinical forms of the disease,

• interfering treatments and associated diseases.

Related Conditions & MeSH terms

• Neuroblastoma

Locations

Country	Name	City	State
France	Service de Pharmacie - Stérilisation - CHU de Strasbourg - France	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of two methods of treating a pediatric pathology in two French health establishments, the HUS and the Oncopole of Toulouse.	This study is retrospective and consists of comparing two methods of treating neuroblastoma in two health establishments and covers the period from January 1, 1998 to December 31, 2023.	The period concerned is from January 1, 1998 to December 31, 2023.